The U.S. Food and Drug Administration (FDA) sent over 50 warning letters to GLP-1 drug compounders and manufacturers in September 2025. The agency warned the companies that their statements that ...
The Food and Drug Administration sends warning letters to entities under its jurisdiction as part of its enforcement activities. Some letters are not posted for public view until weeks or months after ...
The Food and Drug Administration sends warning letters to entities under its jurisdiction as part of its enforcement activities. Some letters are not posted for public view until weeks or months after ...
The FDA this month issued a warning letter to ImmunityBio regarding promotional statements about cancer drug Anktiva that the agency claims are “false or misleading.” The missive marks the first ...
The U.S. Food and Drug Administration (FDA) uses warning letters to notify manufacturers that they have violated the FDA’s regulations or federal law. Manufacturers that receive warning letters must ...
A seafood company failed to follow federal safety rules to prevent potential botulism contamination. A business was hawking dietary supplements with the misleading claim that they’d cure, treat or ...
Please provide your email address to receive an email when new articles are posted on . The FDA found “serious violations” of postmarketing adverse drug experience regulations at Novo Nordisk in 2025.
The enforcement action was announced alongside President Donald Trump's signing of a presidential memorandum.
The US Food and Drug Administration (FDA) has warned an oncology drug company for repeatedly overstating the efficacy of its drug in advertisements while failing to adequately disclose the associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results